Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Moderate Buy” by Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $54.50.

A number of equities analysts have commented on the company. Wall Street Zen upgraded Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Canaccord Genuity Group initiated coverage on Eton Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $60.00 price target on the stock. HC Wainwright raised their price target on Eton Pharmaceuticals from $57.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Finally, Zacks Research downgraded Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th.

Key Headlines Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $65 price target for Eton Pharmaceuticals (ETON). The target implies meaningful upside from recent trading levels and indicates confidence in the company’s longer-term growth prospects.
• Positive Sentiment: The firm expects earnings to strengthen through 2027, forecasting EPS of $0.26 in Q1, $0.30 in Q2, $0.36 in Q3 and $0.35 in Q4. These estimates suggest improving profitability beyond 2026.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The figures appear unreliable or incomplete, so they provide little actionable information about trading sentiment.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to $0.52 from $0.68. Quarterly estimates were also reduced: Q2 EPS to $0.11 from $0.15, Q3 to $0.17 from $0.23 and Q4 to $0.19 from $0.25. The revisions point to weaker-than-previously-expected near-term earnings and may weigh on the shares.
• Negative Sentiment: The updated FY2026 forecast is below the broader consensus estimate of $0.75 per share, increasing the risk of future estimate cuts or earnings-related disappointment.

Insiders Place Their Bets

In other news, insider David Krempa sold 19,679 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the transaction, the insider owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. The trade was a 43.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at $1,624,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 150,000 shares of company stock worth $4,853,921 over the last quarter. 16.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several large investors have recently made changes to their positions in ETON. Quarry LP acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $37,000. Legal & General Group Plc bought a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at approximately $74,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Eton Pharmaceuticals in the 2nd quarter valued at approximately $90,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ:ETON opened at $41.58 on Thursday. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -593.92 and a beta of 0.86. Eton Pharmaceuticals has a 1-year low of $14.27 and a 1-year high of $50.18. The company’s fifty day moving average is $38.23 and its two-hundred day moving average is $28.20. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05). The business had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. Equities analysts anticipate that Eton Pharmaceuticals will post 0.67 EPS for the current year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.